ArticleHaematologica2018
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
2 registry-linked trialsOpen access · goldAbstract readCase Reports
In one paragraph
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04582604 phase1 / phase2unknown statusnot on this mapstarted 2020, after this paper: background citation
Ruxolitinib and Decitabine Intensified Conditioning Regimen for Patients With High Risk Hematological Malignancies Underwenting Allogeneic Stem Cell Transplantation
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen for Patients With Acute B Cell Lymphoblast Leukemia Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation
Who cites it
36 citing papers in PubMed, 66 citations in OpenAlex.
- Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026Review
- PACLseq: A Standalone Diagnostic Method for Ph-Like Acute Lymphoblastic Leukemia Using Nanopore Sequencing.MedComm · 2025Article
- The Mechanisms of Resistance to JAK Inhibitors in Lymphoid Leukemias: A Scoping Review of Evidence from Preclinical Models and Case Reports.International journal of molecular sciences · 2025Article
- JAK2 in pediatric leukemia: mechanisms of pathogenesis and drug development - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Review
- Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities.Diagnostics (Basel, Switzerland) · 2023Review
- BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.Molecular cytogenetics · 2023Article
- Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.Annals of hematology · 2023Review
- JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.International journal of molecular sciences · 2023Article
- Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.British journal of haematology · 2023Article
- Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia.Frontiers in oncology · 2023Article
- Clinical screening for Ph-like ALL and the developing role of TKIs.Hematology. American Society of Hematology. Education Program · 2022Article
- Case Report: Whole genome sequencing identifiesFrontiers in pediatrics · 2022Article
- Review
- Article
- Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?Best practice & research. Clinical haematology · 2021Review
- Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia.Cancers · 2021Article
- Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.NPJ precision oncology · 2021Article
- Targeted Therapy in Acute Lymphoblastic Leukaemia.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Yang Y DingChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA.
Julie W SternChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA.
Tracey F JubelirerChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA.
Gerald B WertheimUniversity of Pennsylvania Perelman School of Medicine, Department of Pathology and Laboratory, PA, USA.
Fumin LinChildren's Hospital of Philadelphia, Division of Genomic Diagnostics Medicine; Children's Hospital of Philadelphia, Division of Hematopathology PA, USA.
Fengqi ChangChildren's Hospital of Philadelphia, Division of Genomic Diagnostics Medicine; Children's Hospital of Philadelphia, Division of Hematopathology PA, USA.
Zhaohui GuSt Jude Children's Research Hospital, Department of Pathology, Memphis, TN, USA.
Charles G MullighanSt Jude Children's Research Hospital, Department of Pathology, Memphis, TN, USA.
Yong LiChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA.
Richard C HarveyUniversity of New Mexico, Department of Pathology and Hematologic Malignancies Research Program, Albuquerque, NM, USA.
I-Ming ChenUniversity of New Mexico, Department of Pathology and Hematologic Malignancies Research Program, Albuquerque, NM, USA.
Cheryl L WillmanUniversity of New Mexico, Department of Pathology and Hematologic Malignancies Research Program, Albuquerque, NM, USA.
Stephen P HungerChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA.
Marilyn M LiChildren's Hospital of Philadelphia, Division of Genomic Diagnostics Medicine; Children's Hospital of Philadelphia, Division of Hematopathology PA, USA.
Sarah K TasianChildren's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA tasians@email.chop.edu.
Children's Hospital of Philadelphia · USUniversity of New Mexico · USUniversity of Pennsylvania · USSt. Jude Children's Research Hospital · US
Funding
T32 Institutional Pediatric ResearchT32HD043021 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI Joseph W. St. Geme · 2002 to 2026
$6.4MPI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic LeukemiaK08CA184418 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI TASIAN, SARAH KATHLEEN · 2014 to 2018
$848kIntegration of gene expression patterns, fusions, mutations, cytogenetics and other clinical variables for subtyping leukemias and targeting therapiesR50CA211542 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HARVEY, RICHARD C · 2016 to 2020
$773kNCI NIH HHS K08 CA184418NCI NIH HHS R50 CA211542NICHD NIH HHS T32 HD043021
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsChildGolgi Matrix ProteinsHumansIn Situ Hybridization, FluorescenceJanus Kinase 2KaryotypingMaleMolecular Targeted TherapyNitrilesOncogene Proteins, FusionPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsPyrazolesPyrimidinesGOLGA5 protein, humanGolgi Matrix ProteinsJAK2 protein, humanJanus Kinase 2NitrilesOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesPyrimidinesruxolitinibVesicular Transport Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04582604ClinicalTrials.gov
NCT05088226ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.